Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids

Patient-derived pancreatic cancer organoids grown in engineered matrices acquire chemoresistance due to the increased expression of drug efflux transporters, promoted by CD44 receptor interactions with hyaluronan in the stiffer tumoural matrix.